<DOC>
	<DOCNO>NCT00673296</DOCNO>
	<brief_summary>Diabetic premacular hemorrhage occur blood preretinal neovascular tissue entrap retina posterior hyaloid macular area . It may occur spontaneously secondary traction localize posterior vitreous detachment . This complication may greatly disturb central vision may important stimulant fibrovascular proliferation . Bevacizumab ( Avastin , Genentech , Inc. ) humanize monoclonal antibody vascular endothelial growth factor ( VEGF ) , use treat variety neovascular ocular disease . In proliferative diabetic retinopathy , intravitreal bevacizumab show induce prompt regression neovascularization may enhance resolution vitreous hemorrhage . In study , propose simultaneous intravitreal injection gas bevacizumab may useful treatment option diabetic premacular hemorrhage active fibrovascular tissue . In procedure , gas use displace blood bevacizumab may render neovascularization less active decrease likelihood recurrent hemorrhage .</brief_summary>
	<brief_title>Intravitreal Injection Bevacizumab Gas Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation</brief_title>
	<detailed_description>In study , consecutive case acute diabetic premacular hemorrhage active fibrovascular proliferation receive intravitreal injection bevacizumab ( 1.25 mg 0.05 mL ) C3F8 ( 0.2-0.3 mL ) setting . Before intravitreal injection , patient either complete panretinal photocoagulation ( PRP ) treatment PRP peripheral retina . After treatment , patient maintain prone position three day follow regular interval . After vitreous clear-up , supplementary PRP extend beyond equator do . Snellen best-corrected visual acuity measurement , intraocular pressure , slit-lamp examination non-contact lens biomicroscopic examination perform treatment follow-up visit . Data include extent premacular hemorrhage , interval treatment clear premacular hemorrhage also record .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Acute diabetic premacular hemorrhage minor active fibrovascular proliferation Anticoagulant therapy Blood disease associate abnormal coagulation Proliferative retinopathy severe enough warrant vitrectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Diabetic premacular hemorrhage</keyword>
	<keyword>Intravitreal gas</keyword>
</DOC>